Loading organizations...
Key people at Nexus NeuroTech Ventures.
Nexus NeuroTech Ventures was founded in 2023 by Jordi Parramon (CEO, General Partner and Co-founder) and William J. Marks, Jr., MD, MS (CMO, General Partner, & Co-Founder).
Nexus NeuroTech Ventures operates as an investment firm, dedicated to advancing pioneering technologies for neurological and psychiatric disorders. It focuses on diverse solutions, including medical devices, software, hardware, and diagnostics for brain-related conditions. This approach aims to translate research into impactful clinical applications, fostering innovations that address unmet needs in brain health.
Established in late 2023, Nexus NeuroTech Ventures was founded on the insight that significant technological innovation was crucial for addressing complex neuro-disorders. The firm aimed to provide specialized financial backing and strategic guidance to emerging companies in this therapeutic domain, recognizing the unique challenges and immense potential within neurotechnology.
The firm primarily serves early-stage neurotechnology companies, whose advancements benefit patients contending with neurological and psychiatric conditions. Nexus NeuroTech Ventures' vision is to accelerate the development and accessibility of transformative technologies, thereby improving outcomes and enhancing the quality of life for individuals affected by brain disorders globally.
Key people at Nexus NeuroTech Ventures.
Nexus NeuroTech Ventures was founded in 2023 by Jordi Parramon (CEO, General Partner and Co-founder) and William J. Marks, Jr., MD, MS (CMO, General Partner, & Co-Founder).
Nexus NeuroTech Ventures has 3 tracked investments across 3 companies. The latest tracked deal is $86.0M Series B in Beacon Biosignals in November 2025.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 13, 2025 | Beacon Biosignals | $86.0M Series B | — | Anthony Philippakis, Pavel Raifeld, Casdin Capital, Jacob Vogelstein, General Catalyst, Indicator Ventures, Logos Capital, Section 32, Takeda |
| Jan 1, 2025 | Nobi | $37.0M Series B | Angelini Ventures, Nexus Neurotech Ventures | 15th Rock Ventures |
| Jan 1, 2024 | Rune Labs | $12.0M Series U | Nexus Neurotech Ventures | Eclipse Ventures, Foundation Capital, Pathbreaker Ventures, Softbank Group, DigiTx Partners, Moment Ventures, TruVenturo |